Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 22, 2021 11:57am
155 Views
Post# 33898507

RE:RE:RE:RE:RE:Oups

RE:RE:RE:RE:RE:OupsGood eye! While I hope Mr. Boucher has not been let go as I never like to see someone lose their job, some of the screw-ups have been pretty bad. Perhaps the two press releases never making it to the wire services were the last straw with him?

Also, I thought I should pass this along. The NBF analyst put out a short note on the news on IV Push today, which makes sense. What doesn't make sense to me is that the NBF analyst failed to put out a note on the NASH KOF last week and I would suggest that the KOL was at least 50 times more significant for TH than any news on IV Push. But writing something up on the KOL might have forced him to conclude that TH's share price should include somme value for NASH. So, he ignored it instead.

TH needs more and better analysts. Messing up on a couple of press releases is not great but being unable to improve the analyst coverage at TH (and in fact seeing it deteriorate significantly over the last  two years from an already low base) is at least 50 times as important as that.

Wino115 wrote: Price needs something more significant. Don't expect much until human data on projects starts coming through.  By the way, anyone else notice that this is the first PR I can recall where it only has Leah as the contact.  They've ditched Denis Boucher as head of PR being listed.  Perhaps a sign that is where some of the issues in communications and PR came from?

PWIB123 wrote: The selling pressure continues no matter the news. This is ridiculous, but I don't think the IV push was really ever going to be a catalyst. This does continue to reinforce everything we've discussed here.




<< Previous
Bullboard Posts
Next >>